.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Express Scripts
Fuji
Baxter
Novartis
US Army
Accenture
Julphar
Cerilliant
Federal Trade Commission

Generated: December 16, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,514,980

« Back to Dashboard

Which drugs does patent 6,514,980 protect, and when does it expire?


Patent 6,514,980 protects XERESE and is included in one NDA.

This patent has thirty patent family members in twenty-six countries.

Summary for Patent: 6,514,980

Title: Nucleoside analogs in combination therapy of herpes simplex infections
Abstract:A pharmaceutical product comprising a nucleoside analogue active against herpes simplex virus, such as acyclovir/valaciclovir or penciclorivir/famciclovir, and an immunosuppressant, as a combined preparation for simultaneous, separate or sequential use in the treatment and/or prevention of herpes simplex virus infections.
Inventor(s): Boyd; Malcolm Richard (Epsom, GB)
Assignee: Novartis International Pharmaceutical Ltd. (Hamilton, BM)
Application Number:09/626,015
Patent Claim Types:
see list of patent claims
Composition; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Valeant BermudaXERESEacyclovir; hydrocortisoneCREAM;TOPICAL022436-001Jul 31, 2009RXYesYes► Subscribe► SubscribeYCOMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND CHILDREN (6 YEARS OF AGE AND OLDER)► Subscribe
Valeant BermudaXERESEacyclovir; hydrocortisoneCREAM;TOPICAL022436-001Jul 31, 2009RXYesYes► Subscribe► SubscribeYNEW COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND ADOLESCENTS (12 YEARS OF AGE AND OLDER)► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,514,980

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9601544Jan 26, 1996

International Patent Family for Patent: 6,514,980

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan493985► Subscribe
Turkey9801439► Subscribe
Slovenia876146► Subscribe
Portugal876146► Subscribe
Poland187076► Subscribe
Poland327917► Subscribe
New Zealand326839► Subscribe
Norway316355► Subscribe
Norway983402► Subscribe
Japan2000507211► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKesson
Fuji
QuintilesIMS
McKinsey
Express Scripts
Cipla
Colorcon
Daiichi Sankyo
Farmers Insurance
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot